{"DataElement":{"publicId":"2730461","version":"1","preferredName":"Concomitant Medication Received Breast Carcinoma Treatment Type","preferredDefinition":"Text term(s) to identify breast cancer specific concomitant treatment agents taken by an individual. [Manually-curated]","longName":"CONCOM_BR_CA_MED_TP","context":"NCIP","contextVersion":"1","DataElementConcept":{"publicId":"2414579","version":"1","preferredName":"Concomitant Breast Medication Received","preferredDefinition":"information relating to concomitant medication received in a breast cancer treatment trial.","longName":"CONCOM_BRST_MED_RECD","context":"CTEP","contextVersion":"2.31","ObjectClass":{"publicId":"2414577","version":"1","preferredName":"Concomitant Breast Medication","preferredDefinition":"Concomitant; following as a consequence.:One of two hemispheric projections of variable size situated in the subcutaneous layer over the pectoralis major muscle on either side of the chest.:biologically active substance, including those intended for use in diagnosis, treatment, or prevention of disease or other abnormalities, for the relief of suffering, or control or improvement of a physical or mental state; includes biological products.","longName":"C25730:C12971:C459","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Concomitant","conceptCode":"C25730","definition":"Accessory, accompanying especially in a subordinate or incidental way, occurring or existing during the same period of time.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"Breast","conceptCode":"C12971","definition":"One of two hemispheric projections of variable size situated in the subcutaneous layer over the pectoralis major muscle on either side of the chest.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Medication","conceptCode":"C459","definition":"A drug product that contains one or more active and/or inactive ingredients; it is intended to treat, prevent or alleviate the symptoms of disease. This term does not refer to the individual ingredients that make up the product.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"0250F635-B025-5B64-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-10-04","endDate":null,"createdBy":"SHIDED","dateCreated":"2005-10-04","modifiedBy":"ONEDATA","dateModified":"2005-10-04","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"Property":{"publicId":"2241679","version":"1","preferredName":"Received","preferredDefinition":"Received; taken, gotten, or acquired.","longName":"C25639","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Receive","conceptCode":"C25639","definition":"To take, accept, or get something offered.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Application","id":"F9FD4EEB-2368-0B27-E034-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-07-09","endDate":null,"createdBy":"SHIDED","dateCreated":"2005-07-09","modifiedBy":"ONEDATA","dateModified":"2005-07-09","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ConceptualDomain":{"publicId":"2008538","version":"1","preferredName":"Therapies","preferredDefinition":"actions or administration of therapeutic agents to produce an effect that is intended to alter the course of a pathologic process (NCI).","longName":"TX","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B214D04D-9F05-1CA5-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-18","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-18","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"0250283E-747A-119F-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-10-04","endDate":null,"createdBy":"SHIDED","dateCreated":"2005-10-04","modifiedBy":"SBR","dateModified":"2016-06-06","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ValueDomain":{"publicId":"2730457","version":"1","preferredName":"Breast Carcinoma Treatment Type","preferredDefinition":"A carcinoma arising from the breast, most commonly the terminal ductal-lobular unit.  Breast carcinoma may affect both females and males.  It is the most common malignant tumor and the leading cause of carcinoma death in women.  Risk factors include country of birth, family history, menstrual and reproductive history, fibrocystic disease and epithelial hyperplasia, exogenous estrogens, contraceptive agents, and ionizing radiation.  The widespread use of mammography has contributed in the detection of very early cancerous lesions (less than 2mm in diameter).  The vast majority of breast carcinomas are adenocarcinomas (ductal or lobular).  Breast carcinoma spreads by direct invasion, by the lymphatic route, and by the blood vessel route.  The most common site of lymph node involvment is the axilla.  Breast carcinomas infrequently occur in males (particularly elderly individuals and patients with Klinefelter's syndrome).  The therapy of breat carcinoma includes surgery, radiation therapy, hormonal therapy and chemotherapy, depending on the type and extend of the disease. --2002_An action or administration of therapeutic agents to produce an effect that is intended to alter the course of a pathologic process._Type; a subdivision of a particular kind of thing.","longName":"BRST_CA_TX_TP","context":"NCIP","contextVersion":"1","type":"Enumerated","dataType":"CHARACTER","minLength":null,"maxLength":"16","minValue":null,"maxValue":null,"decimalPlace":null,"PermissibleValues":[{"value":"Other (specify)","valueDescription":"Other (specify)","ValueMeaning":{"publicId":"2568174","version":"1","preferredName":"Other (specify)","longName":"2568174","preferredDefinition":"Be specific about something; define clearly.: Different than the one(s) previously specified or mentioned.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Specify","conceptCode":"C25685","definition":"Be specific about something; define clearly.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Other","conceptCode":"C17649","definition":"Different than the one(s) previously specified or mentioned.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-D75B-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2004-01-27","endDate":null,"createdBy":"REEVESD","dateCreated":"2004-01-27","modifiedBy":"COOPERM","dateModified":"2015-04-08","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"469A09A4-B4E0-4C83-E044-0003BA3F9857","beginDate":"2008-02-20","endDate":null,"createdBy":"REEVESD","dateCreated":"2008-02-20","modifiedBy":"REEVESD","dateModified":"2008-02-20","deletedIndicator":"No"},{"value":"AI","valueDescription":"Aromatase inhibitor","ValueMeaning":{"publicId":"2571015","version":"1","preferredName":"Aromatase inhibitor","longName":"2571015","preferredDefinition":"An agent that blocks the function of the enzyme aromatase with antineoplastic activity.  Aromatase inhibitors belong to two classes: Type I steroidal drugs are androgen substrate analogues that bind competitively but irreversibly to the enzyme.  Type II nonsteroidal inhibitors fit into the substrate binding site and bind reversibly to the enzyme.  Present in many tissues, aromatases are heme-containing enzymes that catalyze the adrenal conversion of cholesterol to pregnenolone and the peripheral conversion (aromatization) of androgenic precursors to estrogens. (NCI04)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Aromatase Inhibitor","conceptCode":"C1740","definition":"Any substance that inhibits aromatase, an enzyme responsible for the conversion of cholesterol to pregnenolone and the peripheral aromatization of androgenic precursors into estrogens. Inhibition of aromatase results in the suppression of estrogen-regulated processes.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-E274-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2004-07-07","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2004-07-07","modifiedBy":"ALAIS","dateModified":"2007-06-01","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"469A09A4-B4ED-4C83-E044-0003BA3F9857","beginDate":"2008-02-20","endDate":null,"createdBy":"REEVESD","dateCreated":"2008-02-20","modifiedBy":"REEVESD","dateModified":"2008-02-20","deletedIndicator":"No"},{"value":"SERD","valueDescription":"Selective Estrogen Receptor Down-Regulator","ValueMeaning":{"publicId":"2730458","version":"1","preferredName":"Selective Estrogen Receptor Down-Regulator","longName":"2730458","preferredDefinition":"Selective Estrogen Receptor Down-Regulator","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"469A09A4-B4F9-4C83-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":null,"endDate":null,"createdBy":"REEVESD","dateCreated":"2008-02-20","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"469A09A4-B512-4C83-E044-0003BA3F9857","beginDate":"2008-02-20","endDate":null,"createdBy":"REEVESD","dateCreated":"2008-02-20","modifiedBy":"REEVESD","dateModified":"2008-02-20","deletedIndicator":"No"},{"value":"SERM","valueDescription":"Selective Estrogen Receptor Modulator","ValueMeaning":{"publicId":"2730459","version":"1","preferredName":"Selective Estrogen Receptor Modulator","longName":"2730459","preferredDefinition":"Selective Estrogen Receptor Modulator","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"469A09A4-B51E-4C83-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":null,"endDate":null,"createdBy":"REEVESD","dateCreated":"2008-02-20","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"469A09A4-B537-4C83-E044-0003BA3F9857","beginDate":"2008-02-20","endDate":null,"createdBy":"REEVESD","dateCreated":"2008-02-20","modifiedBy":"REEVESD","dateModified":"2008-02-20","deletedIndicator":"No"},{"value":"OS","valueDescription":"Ovarian suppression","ValueMeaning":{"publicId":"2571016","version":"1","preferredName":"Ovarian suppression","longName":"2571016","preferredDefinition":"Ovarian suppression","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-E275-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2004-07-07","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2004-07-07","modifiedBy":"CAMPBELB","dateModified":"2004-07-07","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"469A09A4-B54C-4C83-E044-0003BA3F9857","beginDate":"2008-02-20","endDate":null,"createdBy":"REEVESD","dateCreated":"2008-02-20","modifiedBy":"REEVESD","dateModified":"2008-02-20","deletedIndicator":"No"}],"ConceptualDomain":{"publicId":"2008538","version":"1","preferredName":"Therapies","preferredDefinition":"actions or administration of therapeutic agents to produce an effect that is intended to alter the course of a pathologic process (NCI).","longName":"TX","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B214D04D-9F05-1CA5-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-18","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-18","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"RepresentationTerm":{"publicId":"2730456","version":"1","preferredName":"Breast Carcinoma Treatment Type","preferredDefinition":"A carcinoma arising from the breast, most commonly the terminal ductal-lobular unit.  Breast carcinoma may affect both females and males.  It is the most common malignant tumor and the leading cause of carcinoma death in women.  Risk factors include country of birth, family history, menstrual and reproductive history, fibrocystic disease and epithelial hyperplasia, exogenous estrogens, contraceptive agents, and ionizing radiation.  The widespread use of mammography has contributed in the detection of very early cancerous lesions (less than 2mm in diameter).  The vast majority of breast carcinomas are adenocarcinomas (ductal or lobular).  Breast carcinoma spreads by direct invasion, by the lymphatic route, and by the blood vessel route.  The most common site of lymph node involvment is the axilla.  Breast carcinomas infrequently occur in males (particularly elderly individuals and patients with Klinefelter's syndrome).  The therapy of breat carcinoma includes surgery, radiation therapy, hormonal therapy and chemotherapy, depending on the type and extend of the disease. --2002:An action or administration of therapeutic agents to produce an effect that is intended to alter the course of a pathologic process.:Type; a subdivision of a particular kind of thing.","longName":"C4872:C0087111:C25284","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Breast Carcinoma","conceptCode":"C4872","definition":"A carcinoma arising from the breast, most commonly the terminal ductal-lobular unit. It is the most common malignant tumor in females. Risk factors include country of birth, family history, menstrual and reproductive history, fibrocystic disease and epithelial hyperplasia, exogenous estrogens, contraceptive agents, and ionizing radiation. The vast majority of breast carcinomas are adenocarcinomas (ductal or lobular). Breast carcinoma spreads by direct invasion, by the lymphatic route, and by the blood vessel route. The most common site of lymph node involvement is the axilla.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"Treatment","conceptCode":"C0087111","definition":"An action or administration of therapeutic agents to produce an effect that is intended to alter the course of a pathologic process.","evsSource":"UMLS_CUI","primaryIndicator":"No","displayOrder":"1"},{"longName":"Type","conceptCode":"C25284","definition":"Something distinguishable as an identifiable class based on common qualities.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"469A0931-4530-47E4-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2008-02-20","endDate":null,"createdBy":"REEVESD","dateCreated":"2008-02-20","modifiedBy":"ONEDATA","dateModified":"2008-02-20","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"469A0931-4541-47E4-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2008-02-20","endDate":null,"createdBy":"REEVESD","dateCreated":"2008-02-20","modifiedBy":"SBR","dateModified":"2008-12-08","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ClassificationSchemes":[{"publicId":"2008601","version":"1","longName":"C3D Domain","context":"CCR","ClassificationSchemeItems":[{"publicId":"2812367","version":"1","longName":"caBIG","context":"CCR"}]},{"publicId":"2182125","version":"1","longName":"CCR Implementation","context":"CCR","ClassificationSchemeItems":[{"publicId":"2811673","version":"1","longName":"C3D","context":"CCR"}]},{"publicId":"2183535","version":"1","longName":"Clinical Trial Mgmt Systems","context":"NCIP","ClassificationSchemeItems":[{"publicId":"2812625","version":"1","longName":"CTMS C3D Adopter Sites","context":"NCIP"},{"publicId":"2812731","version":"1","longName":"U Washington","context":"NCIP"},{"publicId":"2812732","version":"1","longName":"FES Study","context":"NCIP"},{"publicId":"2812734","version":"1","longName":"U Washington New CDEs","context":"NCIP"}]}],"AlternateNames":[],"ReferenceDocuments":[{"name":"Therapy Type","type":"Preferred Question Text","description":"Therapy Type","url":null,"context":"NCIP"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Qualified","id":"469A3811-5767-549D-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2008-02-20","endDate":null,"createdBy":"REEVESD","dateCreated":"2008-02-20","modifiedBy":"REEVESD","dateModified":"2011-03-18","changeDescription":"Curated to support U Washington adoption of C3D for FES trial.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"}}